The 7 major partial epilepsy markets are expected to exhibit a CAGR of 9.8% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2035
|
Historical Years
|
2019-2024
|
Market Growth Rate 2025-2035 | 9.8% |
The partial epilepsy market has been comprehensively analyzed in IMARC's new report titled "Partial Epilepsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Partial epilepsy, also known as focal epilepsy, is a type of epilepsy in which seizures begin in a specific area or focus of the brain rather than diffusely across the entire brain. The symptoms associated with the ailment vary depending on the location of the seizure focus. Simple partial seizures may cause sensory disturbances (such as tingling or numbness), visual or auditory hallucinations, altered taste or smell, involuntary movements, intense emotions, etc. Complex partial seizures often involve confusion, unresponsiveness, repetitive motions, post-seizure disorientation, etc. The diagnostic process typically begins with a detailed medical history, including a description of the seizure episodes and any associated symptoms or triggers. The primary diagnostic tool used is an electroencephalogram (EEG), which records electrical activity in the brain and can detect abnormalities indicative of seizures. Additionally, numerous imaging studies, such as MRI and CT scans, are often utilized to identify any structural defects in the brain, like tumors, vascular malformations, signs of past brain injury, etc., that might be the underlying cause of seizures. Various other procedures, including neuropsychological assessments and blood tests, may be conducted to rule out conditions that could induce similar symptoms.
The increasing cases of head injuries, such as those caused by trauma, accidents, falls, etc., that disrupt normal brain functioning are primarily driving the partial epilepsy market. In addition to this, the rising prevalence of various associated risk factors, including certain developmental disorders like neurofibromatosis, structural abnormalities in the brain, hormonal changes, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiepileptic drugs, such as carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, etc., for stabilizing abnormal electrical activity in the brain and reducing the likelihood of seizures is further bolstering the market growth. Apart from this, the escalating application of responsive neurostimulation, which involves the implantation of a device directly into the brain to deliver electrical stimulation when unusual activity is detected, thereby helping to disrupt seizures before they occur, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive brain stimulation techniques, including transcranial direct current stimulation (tDCS), since they aid in modulating brain activity and improving overall seizure control, is expected to drive the partial epilepsy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the partial epilepsy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for partial epilepsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the partial epilepsy market in any manner.
Lamictal (Lamotrigine), an anticonvulsant drug used to treat partial epilepsy. It regulates neuronal activity by blocking voltage-sensitive sodium channels, which reduces excessive electrical activity in the brain. To manage seizures in epileptic patients, Lamictal is recommended as monotherapy or supplementary medication.
Trileptal (Oxcarbazepine), an antiepileptic medication used to treat partial epilepsy. It works by regulating hyperactive nerve impulses in the brain via sodium channel regulation, so preventing seizures. Trileptal is used as monotherapy or supplementary medication to treat partial-onset seizures in both adults and children.
ONO-2017 (Cenobamate) is an investigational anticonvulsant medication being studied for the adjunctive treatment of partial-onset seizures in adults with epilepsy. It works by modulating sodium channels and enhancing GABAergic neurotransmission to reduce seizure frequency and improve seizure control. The dual mechanism of Cenobamate helps stabilize neuronal activity and restore balance in brain excitability. This study is being conducted exclusively in Japan.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current partial epilepsy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Lamictal (Lamotrigine) | GSK plc. |
Trileptal (Oxcarbazepine) | Novartis |
Vimpat (Lacosamide) | UCB |
Carbatrol (Carbamazepine controlled release) | Takeda Pharmaceutical |
Aptiom (Eslicarbazepine acetate) | Sumitomo Pharma |
Fycompa (Perampanel) | Catalyst Pharmaceuticals |
ONO-2017 (Cenobamate) | SK Biopharmaceuticals |
BHV 7000 | Biohaven Ltd. |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Partial Epilepsy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies